Search results for GIP
Industry
Lilly\'s next-generation obesity drug retatrutide shows 25 percent weight loss in 80 weeks
Eli Lilly\'s next-generation obesity drug candidate retatrutide showed an average 25 percent weight loss at the highest dose after 80 weeks in a Phase 3 trial. Among participants who extended treatment to 104 weeks, average weight loss rose to 30 percent. Results were published in the New England Journal of Medicine, with more than one-third losing at least 30 percent of body weight. The study did not directly compare retatrutide with existing obesity drugs, and researchers said further trials are needed.
Crypto
Goldfinch decentralised credit protocol shifts to maintenance mode, halts development
Goldfinch, a decentralised credit protocol, is effectively moving toward shutting down after a token-holder vote. A proposal submitted by co-founders Mike Sall and Blake West cleared quorum by more than four times as of June 23, with about 1.1 million GFI tokens counted in favour and none against. If approved, Goldfinch will stop new protocol development and growth initiatives and focus on loan recovery and maintaining user access.
Industry
Lily\'s new obesity drug retatrutide eyes beyond GLP-1 limits tagged with fatigue
Eli Lilly\'s next-generation obesity treatment retatrutide may reduce fatigue, a side effect often associated with GLP-1 drugs, by regulating energy metabolism as well as suppressing appetite. Retatrutide is designed as a triple agonist that stimulates GLP-1, GIP and glucagon receptors. This mechanism could promote fat and glycogen breakdown while boosting insulin and limiting blood sugar spikes. Gigazine said clinical data are not yet sufficient to confirm the effect.